In clinical practice, it has become apparent that monoclonal antibodies against VEGF and its receptor, VEGFR2, are effective in patients with CRC-derived liver metastases although overall therapeutic efficacy is often limited due to the development of resistance against treatment. This evidence concerns the gene VEGFA and colorectal carcinoma.